Literature DB >> 12448592

Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen.

J M Davies1, R Barnes, D Milligan.   

Abstract

Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen were first published by the British Committee for Standards in Haematology in 1996. Key aspects of these guidelines related to anti-infective prophylaxis, immunisation schedules and treatment of proven or suspected infection. A recent review of the guidelines was undertaken, with a view to updating the recommendations where necessary The guideline review process did not reveal any major change in patient groups considered at risk. Occupational exposure to certain pathogens may, however, be a new risk factor for some infections. The recommendations for anti-infective prophylaxis remain unchanged. New recommendations for vaccination include the use of meningococcal group C vaccine in previously non-immunised hyposplenic patients and a need to consider the use of seven-valent pneumococcal vaccine. Recommendations for treatment of suspected or proven infection have not been significantly amended, but a local protocol should take into account relevant resistance patterns. There is an identified urgent need for further research into the effectiveness of varying vaccination strategies in the hyposplenic patient, and audit of infective episodes in this patient group should continue long term. Key guidelines are summarised below, together with grades of recommendation.

Entities:  

Mesh:

Year:  2002        PMID: 12448592      PMCID: PMC4953085          DOI: 10.7861/clinmedicine.2-5-440

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  52 in total

1.  Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients.

Authors:  A Meerveld-Eggink; O de Weerdt; R M de Voer; G A M Berbers; H van Velzen-Blad; B J Vlaminckx; D H Biesma; G T Rijkers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-24       Impact factor: 3.267

2.  Preventing severe infection after splenectomy.

Authors:  Adrian Newland; Drew Provan; Steven Myint
Journal:  BMJ       Date:  2005-08-20

3.  Vaccination coverage in adults undergoing splenectomy: evaluation of hospital vaccination policies.

Authors:  L Bruni; J M Bayas; A Vilella; A Conesa
Journal:  Epidemiol Infect       Date:  2005-12-22       Impact factor: 2.451

Review 4.  Splenic regeneration following splenectomy and impact on sepsis: a clinical review.

Authors:  Manuel Riera; Simon Buczacki; Zulfiqar A J Khan
Journal:  J R Soc Med       Date:  2009-04       Impact factor: 5.344

5.  Preventing and treating infections in children with asplenia or hyposplenia.

Authors:  Marina I Salvadori; Victoria E Price
Journal:  Paediatr Child Health       Date:  2014-05       Impact factor: 2.253

6.  Management of post-splenectomy patients in the Netherlands.

Authors:  A J J Lammers; D Veninga; M J M H Lombarts; J B L Hoekstra; P Speelman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-01-22       Impact factor: 3.267

7.  Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.

Authors:  Paul Balmer; Michelle Falconer; Paula McDonald; Nick Andrews; Emily Fuller; Christine Riley; Edward Kaczmarski; Raymond Borrow
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 8.  Laparoscopic Splenectomy for Benign Hematological Disorders in Adults: A Systematic Review.

Authors:  Demetrios Moris; Nikoletta Dimitriou; John Griniatsos
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 9.  Cardiac and Non-Cardiac Abnormalities in Heterotaxy Syndrome.

Authors:  Smita Mishra
Journal:  Indian J Pediatr       Date:  2015-11-26       Impact factor: 1.967

10.  [Distal pancreatectomy: radical or spleen-preserving?].

Authors:  A M Chromik; M Janot; D Sülberg; M H Seelig; W Uhl
Journal:  Chirurg       Date:  2008-12       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.